Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866964 · ClinicalTrials.gov registry record · Phase 2
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
A Phase 2 study of Germ Cell Tumor and Testicular Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT06866964 is a Phase 2 study of Germ Cell Tumor and Testicular Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06866964, a Phase 2 study of Germ Cell Tumor and Testicular Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Conditions Studied
Interventions
- DRUG Low-dose ASA
Study Locations (3)
North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Charlotte
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Wisconsin
- Aurora St. Luke's Medical Center MOB - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2031-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06866964
The ClinicalTrials.gov registry entry for NCT06866964 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (90% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Low-dose ASA is the first listed.
NCT06866964 reports 3 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06866964 about?
NCT06866964 is a clinical study titled "A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy". The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
What is the current status of trial NCT06866964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-08-28. Estimated completion is 2031-01.
What conditions does trial NCT06866964 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Testicular Cancer.
What interventions are being tested in trial NCT06866964?
The interventions under investigation include: Low-dose ASA (DRUG).
Who is sponsoring clinical trial NCT06866964?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866964 being conducted?
This trial has 3 study locations across North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.